Status:
COMPLETED
Omega-3 Supplementation and Attention-deficit-hyperactivity Disorder (ADHD)
Lead Sponsor:
Hadassah Medical Organization
Collaborating Sponsors:
Israel Association of Pediatricians
Conditions:
Attention Deficit Hyperactivity Disorder
Eligibility:
All Genders
6-16 years
Phase:
NA
Brief Summary
It is assumed that only 1/5 of children diagnosed with attention-deficit-hyperactivity disorder (ADHD) are treated. New treatment modalities are urgently needed. Omega-3 fatty acids have been used in ...
Eligibility Criteria
Inclusion
- ADHD diagnosis
- informed consent
Exclusion
- refusal of any testing
- any comorbidities
- any medication or supplement use
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00874536
Start Date
April 1 2009
End Date
June 1 2011
Last Update
July 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Jerusalem, Israel, 91120